A Phase 4 interventional study of Caffeine and Losartan in Transplant Rejection, sponsored by Bristol-Myers Squibb. Completed at 1 site in United States. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-06-27.
Sponsored by Bristol-Myers Squibb · Phase 4, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to determine the effects of belatacept on the pharmacokinetics of caffeine, losartan, omeprazole, dextromethorphan and midazolam
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Inje Cocktail consisting of (200 mg Caffeine, 50 mg losartan tablet, 40 mg Omeprazole capsule, 30 mg Dextromethorphan capsule and 5 mg Midazolam oral syrup) administered on Days 1, 4, 7 and 11 Belatacept 10 mg/kg Intravenous (IV) solution, administered on Day 4
Drug: Caffeine · Drug: Losartan · Drug: Omeprazole · Drug: Dextromethorphan · Drug: Midazolam · Biological: Belatacept
Also known as: Nulojix, BMS-224818
Adjusted Geometric Mean Maximum Drug Concentration (Cmax) of Midazolam With and Without the Coadministration of Belatacept - Pharmacokinetic (PK) Evaluable Population
Samples for the assessment of plasma concentrations of Inje cocktail components (midazolam, losartan, omeprazole, dextromethorphan and caffeine) and their metabolites (1'-hydroxy-midazolam, E-3174, 5-hydroxyomeprazole, dextrorphan, and paraxanthine) were collected at time = 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, and 24 hours relative to the dosing of belatacept on Day 4 and Inje cocktail dosing on Days 1, 4, 7, and 11, respectively. Adjusted geometric mean for midazolam with and without belatacept, along with adjusted geometric mean ratios for Days 4, 7, and 11 versus Day 1, respectively, are presented. Cmax measured in nanograms per milliliter (ng/mL). Inje cocktail components (Midazolam) measured using High Performance Liquid Chromatography (HPLC) with Tandem Mass Spectrometry (MS/MS) Detection.
Time frame: Pre-dose to 24 hours after dose of the Inje Cocktail on Days 1, 4, 7 and 11
Adjusted Geometric Mean Area Under the Concentration Time Curve (AUC) From Zero to Last Concentration (0-T) and AUC Extrapolated to Infinity (INF) of Midazolam With and Without the Coadministration of Belatacept - Pharmacokinetic (PK) Evaluable Population
AUC(0-T): area under the plasma concentration-time curve from zero to the last time of the last quantifiable concentration and AUC (INF): AUC from time zero extrapolated to infinite time were measured in ng\*h/mL. Samples for the assessment of plasma concentrations of Inje cocktail components (midazolam, losartan, omeprazole, dextromethorphan and caffeine) and their metabolites (1'-hydroxy-midazolam, E-3174, 5-hydroxyomeprazole, dextrorphan, and paraxanthine) were collected at time = 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, and 24 hours relative to the dosing of belatacept on Day 4 and Inje cocktail dosing on Days 1, 4, 7, and 11, respectively. Adjusted geometric mean for midazolam with and without belatacept, along with adjusted geometric mean ratios for Days 4, 7, and 11 versus Day 1, respectively, are presented. Midazolam measured using HPLC with MS/MS Detection.
Time frame: Pre-dose to 24 hours after dose of the Inje Cocktail on Days 1, 4, 7and 11
Adjusted Geometric Mean Cmax of Losartan With and Without the Coadministration of Belatacept - PK Evaluable Population
Cmax measured in ng/mL. Samples for assessment of plasma concentrations of Inje cocktail components (midazolam, losartan, omeprazole, dextromethorphan and caffeine) and their metabolites (1'-hydroxy-midazolam, E-3174, 5-hydroxyomeprazole, dextrorphan, and paraxanthine) were collected at time = 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, and 24 hours relative to the dosing of belatacept on Day 4 and Inje cocktail dosing on Days 1, 4, 7, and 11, respectively. Adjusted geometric mean for losartan with and without belatacept, along with adjusted geometric mean ratios for Days 4, 7, and 11 versus Day 1, respectively, are presented. Inje cocktail components (losartan) measured using HPLC with MS/MS Detection.
Time frame: Pre-dose to 24 hours after dose of the Inje Cocktail on Days 1, 4, 7 and 11
Adjusted Geometric Mean AUC (0-T) and AUC (INF) of Losartan With and Without the Coadministration of Belatacept - Pharmacokinetic (PK) Evaluable Population
AUC (0-T): area under the concentration curve from time 0 to the time of the last quantifiable concentration and AUC (INF) extrapolated to infinity were measured in ng\*h/mL. Samples for assessment of plasma concentrations of Inje cocktail components (midazolam, losartan, omeprazole, dextromethorphan and caffeine) and their metabolites (1'-hydroxy-midazolam, E-3174, 5-hydroxyomeprazole, dextrorphan, and paraxanthine) were collected at time = 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, and 24 hours relative to the dosing of belatacept on Day 4 and Inje cocktail dosing on Days 1, 4, 7, and 11, respectively. Adjusted geometric mean for losartan with and without belatacept, along with adjusted geometric mean ratios for Days 4, 7, and 11 versus Day 1, respectively, are presented. Inje cocktail components (losartan) measured using HPLC with MS/MS Detection.
Time frame: Pre-dose to 24 hours after dose of the Inje Cocktail on Days 1, 4, 7 and 11
Adjusted Geometric Mean Cmax of Omeprazole With and Without the Coadministration of Belatacept - Pharmacokinetic (PK) Evaluable Population
Cmax: Maximum observed plasma concentration was measured in ng/mL. Samples for assessment of plasma concentrations of Inje cocktail components (midazolam, losartan, omeprazole, dextromethorphan and caffeine) and their metabolites (1'-hydroxy-midazolam, E-3174, 5-hydroxyomeprazole, dextrorphan, and paraxanthine) were collected at time = 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, and 24 hours relative to the dosing of belatacept on Day 4 and Inje cocktail dosing on Days 1, 4, 7, and 11, respectively. Adjusted geometric mean for omeprazole with and without belatacept, along with adjusted geometric mean ratios for Days 4, 7, and 11 versus Day 1, respectively, are presented. Inje cocktail components (omeprazole) measured using HPLC with MS/MS Detection.
Time frame: Pre-dose to 24 hours after dose of the Inje Cocktail on Days 1, 4, 7 and 11
Adjusted Geometric Mean AUC (0-T) and AUC (INF) of Omeprazole With and Without the Coadministration of Belatacept - Pharmacokinetic (PK) Evaluable Population
AUC(0-T): Area under the plasma concentration-time curve from time zero zero to the time of the last quantifiable concentration and AUC (INF): AUC extrapolated to infinity were measured in ng\*h/mL. Samples for assessment of plasma concentrations of Inje cocktail components (midazolam, losartan, omeprazole, dextromethorphan and caffeine) and their metabolites (1'-hydroxy-midazolam, E-3174, 5-hydroxyomeprazole, dextrorphan, and paraxanthine) were collected at time = 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, and 24 hours relative to the dosing of belatacept on Day 4 and Inje cocktail dosing on Days 1, 4, 7, and 11, respectively. Adjusted geometric mean for omeprazole with and without belatacept, along with adjusted geometric mean ratios for Days 4, 7, and 11 versus Day 1, respectively, are presented. Inje cocktail components (omeprazole) measured using HPLC with MS/MS Detection.
Time frame: Pre-dose to 24 hours after dose of the Inje Cocktail on Days 1, 4, 7 and 11
Adjusted Geometric Mean Cmax of Dextromethorphan With and Without the Coadministration of Belatacept - PK Evaluable Population
Cmax was measured in ng/mL. Samples for assessment of plasma concentrations of Inje cocktail components (midazolam, losartan, omeprazole, dextromethorphan and caffeine) and their metabolites (1'-hydroxy-midazolam, E-3174, 5-hydroxyomeprazole, dextrorphan, and paraxanthine) were collected at time = 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, and 24 hours relative to the dosing of belatacept on Day 4 and Inje cocktail dosing on Days 1, 4, 7, and 11, respectively. Adjusted geometric mean for dextromethorphan with and without belatacept, along with adjusted geometric mean ratios for Days 4, 7, and 11 versus Day 1, respectively, are presented. The poor metabolizer of CYP2D6 was excluded from the statistical analysis. Inje cocktail components (dextromethorphan) measured using HPLC with MS/MS Detection.
Time frame: Pre-dose to 24 hours after dose of the Inje Cocktail on Days 1, 4, 7 and 11
Adjusted Geometric Mean AUC (0-T) and AUC (INF) of Dextromethorphan With and Without the Coadministration of Belatacept - PK Evaluable Population
AUC(0-T): area under the plasma concentration-time curve from time zero to the time of the last quantifiable concentration and AUC (INF): AUC extrapolated to infinity, were measured as ng\*h/mL. Samples for assessment of plasma concentrations of Inje cocktail components (midazolam, losartan, omeprazole, dextromethorphan and caffeine) and their metabolites (1'-hydroxy-midazolam, E-3174, 5-hydroxyomeprazole, dextrorphan, and paraxanthine) were collected at time = 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, and 24 hours relative to the dosing of belatacept on Day 4 and Inje cocktail dosing on Days 1, 4, 7, and 11, respectively. Adjusted geometric mean for dextromethorphan with and without belatacept, along with adjusted geometric mean ratios for Days 4, 7, and 11 versus Day 1, respectively, are presented. The poor metabolizer of CYP2D6 was excluded from the statistical analysis. Inje cocktail components (dextromethorphan) measured using HPLC with MS/MS Detection.
Time frame: Pre-dose to 24 hours after dose of the Inje Cocktail on Days 1, 4, 7 and 11
Adjusted Geometric Mean Cmax of Caffeine With and Without the Coadministration of Belatacept - PK Evaluable Population
Samples for assessment of plasma concentrations of Inje cocktail components (midazolam, losartan, omeprazole, dextromethorphan and caffeine) were collected at time = 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, and 24 hours relative to the dosing of belatacept on Day 4 and Inje cocktail dosing on Days 1, 4, 7, and 11, respectively. Inje cocktail components were each measured using HPLC with MS/MS detection. Cmax was measured in ng/mL.
Time frame: Pre-dose to 24 hours after dose of the Inje Cocktail on Days 1, 4, 7 and 11
Adjusted Geometric Mean AUC (0-T) and AUC (INF) of Caffeine With and Without the Coadministration of Belatacept - PK Evaluable Population
Samples for assessment of plasma concentrations of Inje cocktail components (midazolam, losartan, omeprazole, dextromethorphan and caffeine) were collected at time = 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, and 24 hours relative to the dosing of belatacept on Day 4 and Inje cocktail dosing on Days 1, 4, 7, and 11, respectively. Inje cocktail components were each measured using HPLC with MS/MS detection. AUC (0-T) and AUC (INF) were measured as ng\*h/mL.
Time frame: Pre-dose to 24 hours after dose of the Inje Cocktail on Days 1, 4, 7 and 11
Time of Maximum Observed Plasma Concentration (Tmax) of the Inje Cocktail Components (Midazolam, Losartan, Omeprazole, Dextromethorphan, and Caffeine) With and Without Coadministration of Belatacept - PK Evaluable Population
Samples for assessment of plasma concentrations of Inje cocktail components (midazolam, losartan, omeprazole, dextromethorphan and caffeine) were collected at time = 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, and 24 hours relative to the dosing of belatacept on Day 4 and Inje cocktail dosing on Days 1, 4, 7, and 11, respectively. The poor metabolizer of CYP2D6 was excluded from summary of dextromethorphan parameters. Inje cocktail components were each measured using HPLC with MS/MS detection. Tmax was measured in hours (h).
Time frame: Pre-dose to 24 hours after dose of the Inje Cocktail on Days 1, 4, 7 and 11
Plasma Half-Life (T-HALF) of the Inje Cocktail Components (Midazolam, Losartan, Omeprazole, Dextromethorphan, and Caffeine) With and Without Coadministration of Belatacept - PK Evaluable Population
Samples for assessment of plasma concentrations of Inje cocktail components (midazolam, losartan, omeprazole, dextromethorphan and caffeine) were collected at time = 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, and 24 hours relative to the dosing of belatacept on Day 4 and Inje cocktail dosing on Days 1, 4, 7, and 11, respectively. The poor metabolizer of CYP2D6 was excluded from summary of dextromethorphan parameters. Inje cocktail components were each measured using HPLC with MS/MS detection. T-HALF was measured in hours (h).
Time frame: Pre-dose to 24 hours after dose of the Inje Cocktail on Days 1, 4, 7 and 11
Apparent Total Body Clearance (CLT/F) of the Inje Cocktail Components (Midazolam, Losartan, Omeprazole, Dextromethorphan and Caffeine) With and Without Coadministration of Belatacept - PK Evaluable Population
Samples for assessment of plasma concentrations of Inje cocktail components (midazolam, losartan, omeprazole, dextromethorphan and caffeine) were collected at time = 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, and 24 hours relative to the dosing of belatacept on Day 4 and Inje cocktail dosing on Days 1, 4, 7, and 11, respectively. The poor metabolizer of CYP2D6 was excluded from summary of dextromethorphan parameters. Inje cocktail components were each measured using HPLC with MS/MS detection. CLT/F was measured as liters/hour (L/h)
Time frame: Pre-dose to 24 hours after dose of the Inje Cocktail on Days 1, 4, 7 and 11
Cmax of Inje Cocktail Metabolites (1'-Hydroxy-Midazolam, E-3174, 5-Hydroxyomeprazole, Dextrorphan, and Paraxanthine) With and Without Coadministration of Belatacept - PK Evaluable Population
Samples for assessment of plasma concentrations of Inje cocktail component metabolites (1'-hydroxy-midazolam, E-3174, 5-hydroxyomeprazole, dextrorphan, and paraxanthine) were collected at time = 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, and 24 hours relative to the dosing of belatacept on Day 4 and Inje cocktail dosing on Days 1, 4, 7, and 11, respectively. The poor metabolizer of CYP2D6 was excluded from summary of Dextrorphan parameters. Inje cocktail component metabolites were each measured using HPLC with MS/MS detection. Cmax was measured in ng/mL.
Time frame: Pre-dose to 24 hours after dose of the Inje Cocktail on Days 1, 4, 7 and 11
AUC(0-T) of Inje Cocktail Component Metabolites (1'-Hydroxy-Midazolam, E-3174, 5-Hydroxyomeprazole, Dextrorphan, and Paraxanthine) With and Without Coadministration of Belatacept - PK Evaluable Population
Area under the plasma concentration-time curve from zero to the last time of the last quantifiable concentration \[AUC(0-T)\] was measured in ng\*h/mL. Samples for assessment of plasma concentrations of Inje cocktail components metabolites (1'-hydroxy-midazolam, E-3174, 5-hydroxyomeprazole, dextrorphan, and paraxanthine) were collected at time = 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, and 24 hours relative to the dosing of belatacept on Day 4 and Inje cocktail dosing on Days 1, 4, 7, and 11, respectively. The poor metabolizer of CYP2D6 was excluded from summary of Dextrorphan parameters. Inje cocktail components were each measured using HPLC with MS/MS detection.
Time frame: Pre-dose to 24 hours after dose of the Inje Cocktail on Days 1, 4, 7 and 11
AUC(INF) of Inje Cocktail Component Metabolites (1'-Hydroxy-Midazolam, E-3174, 5-Hydroxyomeprazole, Dextrorphan, and Paraxanthine) With and Without Coadministration of Belatacept - PK Evaluable Population
Area under the plasma concentration-time curve from time zero extrapolated to infinite time \[AUC(INF)\] was measured in ng\*h/mL. Samples for assessment of plasma concentrations of Inje cocktail components metabolites (1'-hydroxy-midazolam, E-3174, 5-hydroxyomeprazole, dextrorphan, and paraxanthine) were collected at time = 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, and 24 hours relative to the dosing of belatacept on Day 4 and Inje cocktail dosing on Days 1, 4, 7, and 11, respectively. The poor metabolizer of CYP2D6 was excluded from summary of Dextrorphan parameters. Inje cocktail components were each measured using HPLC with MS/MS detection.
Time frame: Pre-dose to 24 hours after dose of the Inje Cocktail on Days 1, 4, 7 and 11
Tmax of Inje Cocktail Component Metabolites (1'-Hydroxy-Midazolam, E-3174, 5-Hydroxyomeprazole, Dextrorphan, and Paraxanthine) With and Without the Coadministration of Belatacept - PK Evaluable Population
Samples for assessment of plasma concentrations of Inje cocktail components metabolites (1'-hydroxy-midazolam, E-3174, 5-hydroxyomeprazole, dextrorphan, and paraxanthine) were collected at time = 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, and 24 hours relative to the dosing of belatacept on Day 4 and Inje cocktail dosing on Days 1, 4, 7, and 11, respectively. The poor metabolizer of CYP2D6 was excluded from summary of Dextrorphan parameters. Inje cocktail components were each measured using HPLC with MS/MS detection. Time of maximum observed plasma concentration (Tmax) was measured in hours (h).
Time frame: Pre-dose to 24 hours after dose of the Inje Cocktail on Days 1, 4, 7 and 11
T-HALF of Inje Cocktail Component Metabolites (1'-Hydroxy-Midazolam, E-3174, 5-Hydroxyomeprazole, Dextrorphan, and Paraxanthine) With and Without the Coadministration of Belatacept - PK Evaluable Population
Plasma half-life (T-HALF) was measured in hours (h). Samples for assessment of plasma concentrations of Inje cocktail components metabolites (1'-hydroxy-midazolam, E-3174, 5-hydroxyomeprazole, dextrorphan, and paraxanthine) were collected at time = 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, and 24 hours relative to the dosing of belatacept on Day 4 and Inje cocktail dosing on Days 1, 4, 7, and 11, respectively. The poor metabolizer of CYP2D6 was excluded from summary of Dextrorphan parameters. Inje cocktail components were each measured using HPLC with MS/MS detection.
Time frame: Pre-dose to 24 hours after dose of the Inje Cocktail on Days 1, 4, 7 and 11
Ratio of Paraxanthine AUC(0-T) to Caffeine AUC(0-T) and Paraxanthine AUC (INF) to Caffeine AUC (INF), Corrected for Molecular Weight [MR_AUC(0-T) and MR_AUC (INF)] With and Without Coadministration of Belatacept - PK Evaluable Population
Metabolite (paraxanthine) to parent (caffeine) ratio was corrected for molecular weight. AUC (0-T) and AUC (INF) measured in ng\*h/mL. Samples for assessment of plasma concentrations of Inje cocktail components and the metabolites of those components were collected at time = 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, and 24 hours relative to the dosing of belatacept on Day 4 and Inje cocktail dosing on Days 1, 4, 7, and 11, respectively. Inje cocktail components were each measured using HPLC with MS/MS detection.
Time frame: Pre-dose to 24 hours after dose of the Inje Cocktail on Days 1, 4, 7 and 11
Ratio of Paraxanthine (Cmax) to Caffeine (Cmax), Corrected for Molecular Weight (MR_Cmax) With and Without Coadministration of Belatacept - PK Evaluable Population
Metabolite (paraxanthine) to parent (caffeine) ratio was corrected for molecular weight. Cmax measured in ng/mL. Samples for assessment of plasma concentrations of Inje cocktail components and their metabolites were collected at time = 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, and 24 hours relative to the dosing of belatacept on Day 4 and Inje cocktail dosing on Days 1, 4, 7, and 11, respectively. Inje cocktail components were each measured using HPLC with MS/MS detection.
Time frame: Pre-dose to 24 hours after dose of the Inje Cocktail on Days 1, 4, 7 and 11
Ratio of E-3174 AUC(0-T) to Losartan AUC(0-T) and E3174 AUC (INF) to Losartan AUC (INF) Corrected for Molecular Weight [MR_AUC(0-T), MR_AUC(INF)] With and Without Coadministration of Belatacept - PK Evaluable Population
Metabolite (E-3174) to parent (losartan) ratio was corrected for molecular weight. AUC (0-T) and AUC (INF) measured in ng\*h/mL. Samples for assessment of plasma concentrations of Inje cocktail components and the metabolites of those components were collected at time = 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, and 24 hours relative to the dosing of belatacept on Day 4 and Inje cocktail dosing on Days 1, 4, 7, and 11, respectively. Inje cocktail components were each measured using HPLC with MS/MS detection.
Time frame: Pre-dose to 24 hours after dose of the Inje Cocktail on Days 1, 4, 7 and 11
Ratio of E-3174 (Cmax) to Losartan (Cmax), Corrected for Molecular Weight (MR_Cmax) With and Without Coadministration of Belatacept - PK Evaluable Population
Metabolite (E-3174) to parent (losartan) ratio was corrected for molecular weight. Cmax measured in ng/mL. Samples for assessment of plasma concentrations of Inje cocktail components and the metabolites of those components were collected at time = 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, and 24 hours relative to the dosing of belatacept on Day 4 and Inje cocktail dosing on Days 1, 4, 7, and 11, respectively. Inje cocktail components were each measured using HPLC with MS/MS detection.
Time frame: Pre-dose to 24 hours after dose of the Inje Cocktail on Days 1, 4, 7 and 11
Ratio of 5-Hydroxyomeprazole AUC(0-T) to Omeprazole AUC(0-T) and 5-Hydroxyomeprazole AUC(INF) to Omeprazole AUC(INF) , Corrected for Molecular Weight [MR_AUC(0-T), MR_AUC(INF)] With and Without Coadministration of Belatacept - PK Evaluable Population
Metabolite (5-Hydroxyomeprazole) to parent (omeprazole) ratio was corrected for molecular weight. AUC (0-T) and AUC (INF) measured in ng\*h/mL. Samples for assessment of plasma concentrations of Inje cocktail components and the metabolites of those components were collected at time = 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, and 24 hours relative to the dosing of belatacept on Day 4 and Inje cocktail dosing on Days 1, 4, 7, and 11, respectively. Inje cocktail components were each measured using HPLC with MS/MS detection.
Time frame: Pre-dose to 24 hours after dose of the Inje Cocktail on Days 1, 4, 7 and 11
Ratio of 5-Hydroxyomeprazole (Cmax) to Omeprazole (Cmax), Corrected for Molecular Weight (MR_Cmax) With and Without Coadministration of Belatacept - PK Evaluable Population
Metabolite (5-hydroxyomeprazole) to parent (omeprazole) ratio was corrected for molecular weight. Cmax measured in ng/mL. Samples for assessment of plasma concentrations of Inje cocktail components and the metabolites of those components were collected at time = 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, and 24 hours relative to the dosing of belatacept on Day 4 and Inje cocktail dosing on Days 1, 4, 7, and 11, respectively. Inje cocktail components were each measured using HPLC with MS/MS detection.
Time frame: Pre-dose to 24 hours after dose of the Inje Cocktail on Days 1, 4, 7 and 11
Ratio of 5-Dextrorphan AUC(0-T) to Dextromethorphan AUC(0-T) and 5-Dextrorphan AUC(INF) to Dextromethorphan AUC(INF), Corrected for Molecular Weight [MR_AUC(0-T), MR_AUC (INF)] With and Without Coadministration of Belatacept - PK Evaluable Population
Metabolite (5-dextrorphan ) to parent (dextromethorphan) ratio was corrected for molecular weight. AUC (0-T) and AUC (INF) measured in ng\*h/mL. Samples for assessment of plasma concentrations of Inje cocktail components and the metabolites of those components were collected at time = 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, and 24 hours relative to the dosing of belatacept on Day 4 and Inje cocktail dosing on Days 1, 4, 7, and 11, respectively. The poor metabolizer of CYP2D6 was excluded from summary of Dextrorphan parameters. Inje cocktail components were each measured using HPLC with MS/MS detection.
Time frame: Pre-dose to 24 hours after dose of the Inje Cocktail on Days 1, 4, 7 and 11
Ratio of 5-Dextrorphan (Cmax) to Dextromethorphan (Cmax), Corrected for Molecular Weight (MR_Cmax) With and Without Coadministration of Belatacept - PK Evaluable Population
Metabolite (5-dextrorphan) to parent (dextromethorphan) ratio was corrected for molecular weight. Cmax measured in ng/mL. Samples for assessment of plasma concentrations of Inje cocktail components and the metabolites of those components were collected at time = 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, and 24 hours relative to the dosing of belatacept on Day 4 and Inje cocktail dosing on Days 1, 4, 7, and 11, respectively. The poor metabolizer of CYP2D6 was excluded from summary of Dextrorphan parameters. Inje cocktail components were each measured using HPLC with MS/MS detection.
Time frame: Pre-dose to 24 hours after dose of the Inje Cocktail on Days 1, 4, 7 and 11
Ratio of 1'-Hydroxy-Midazolam AUC(0-T) to Midazolam AUC(0-T) and 1'-Hydroxy-Midazolam AUC(INF) to Midazolam AUC(INF), Corrected for Molecular Weight [MR_AUC(0-T), MR_AUC (INF)] With and Without Coadministration of Belatacept - PK Evaluable Population
Metabolite (1'-hydroxy-midazolam) to parent (midazolam) ratio was corrected for molecular weight. AUC (0-T) and AUC (INF) measured in ng\*h/mL. Samples for assessment of plasma concentrations of Inje cocktail components and the metabolites of those components were collected at time = 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, and 24 hours relative to the dosing of belatacept on Day 4 and Inje cocktail dosing on Days 1, 4, 7, and 11, respectively. Inje cocktail components were each measured using HPLC with MS/MS detection.
Time frame: Pre-dose to 24 hours after dose of the Inje Cocktail on Days 1, 4, 7 and 11
Ratio of 1'-Hydroxy-Midazolam (Cmax) to Midazolam (Cmax), Corrected for Molecular Weight (MR_Cmax) With and Without Coadministration of Belatacept - PK Evaluable Population
Metabolite (1'-hydroxy-midazolam) to parent (midazolam) ratio was corrected for molecular weight. Cmax measured in ng/mL. Samples for assessment of plasma concentrations of Inje cocktail components and the metabolites of those components were collected at time = 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, and 24 hours relative to the dosing of belatacept on Day 4 and Inje cocktail dosing on Days 1, 4, 7, and 11, respectively. Inje cocktail components were each measured using HPLC with MS/MS detection.
Time frame: Pre-dose to 24 hours after dose of the Inje Cocktail on Days 1, 4, 7 and 11
Number of Participants With Adverse Events (AEs), Serious AEs (SAEs), Deaths, and AEs Leading to Discontinuation - All Treated Participants
Adverse events were coded according to the Medical Dictionary for Regulatory Activities (MedDRA), version 15.1. AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Events captured from Day 1 (pre-dose) to last day prior to discharge (Day 46 ±2). In the total group, a participant with an AE is only counted once (ie, data reflected in Days 1, 4, 7, and 11 below could be the same participant with an AE on multiple days of the study).
Time frame: Day 1 to Day of discharge (Day 46±2)
Number of Participants With Marked Serum Chemistry Laboratory Abnormalities - All Treated Participants
Samples for laboratory tests were obtained at Screening visit, Day -1 or prior to dosing on Day 1, Days 3, 6, 10, 46, and at early termination, after 10 hours fasting. Upper limits of normal (ULN); Lower limits of normal (LLN); Pre-therapy (Rx); micromoles per liter (µmol/L); millimoles per liter (mmol/L); grams per liter (g/L); Units per liter (U/L); Aspartate Aminotransferase (AST); Blood Urea Nitrogen (BUN) Total Bilirubin: \>1.1\*ULN if Pre-Rx\<= ULN or Pre-Rx is missing, or \>1.2\*Pre-Rx if Pre-Rx \>ULN. AST: \>1.25\*Pre-Rx if Pre-Rx \>ULN or 1.25\*ULN if Pre-Rx \<= ULN or Pre-Rx is missing. BUN: \>1.1\*ULN if Pre-Rx\<= ULN or Pre-Rx is missing, or \>1.2\*Pre-Rx if Pre-Rx \>ULN. Phosphorus: \<0.85\*LLN if Pre-RX \>= LLN or is missing or if Pre-Rx \< LLN. total Protein: \<0.9\*LLN if Pre-Rx\>= LLN or is missing or Pre-Rx \> LLN. Creatine Kinase: \>1.5\*Pre-Rx if Pre-Rx \> ULN or is missing or Pre-Rx is \<= ULN. Lactate Dehydrogenase: \>1.25\*ULN if Pre-Rx \<= ULN or missing, \>1.5\*Pre-Rx if Pre-Rx \> ULN.
Time frame: Day -1 to Day 46 ±2 days or at early termination
Number of Participants With Marked Hematology and Urinalysis Laboratory Abnormalities - All Treated Participants
Samples for laboratory tests were obtained at Screening visit, Day -1 or prior to dosing on Day 1, Days 3, 6, 10, 46 ±2, and at early termination, after 10 hours fasting. Leukocytes: \*10\^9 cells per liter (c/L) \< 0.85\*Pre-Rx if Pre-Rx \< LLN or \<0.9\*LLN if LLN \<= Pre-Rx or Pre-Rx is missing. Neutrophils (absolute): \*10\^12 c/L \< 0.85\* Pre-Rx if Pre-Rx \< 1.5, \<1.5 if Pre-Rx \>= 1.5, \< 1.5 if Pre-Rx missing. Urine blood from dipstick: \>=2 if Pre-Rx \<1 or was missing or if Pre-Rx \>=1. Urinary microscopic white blood cells (WBC) and red blood cells (RBC) \>= 2 if Pre-Rx \<2 or if Pre-Rx was missing or \>=4 if Pre-Rx \>=2.
Time frame: Day -1 to Day 46 ±2 days or at early termination
Number of Participants With Out-of-Range Electrocardiogram Intervals - All Treated Participants
Participants had 12-Lead electrocardiograms (ECGs) performed at Screening Visit, Day 1 prior to dosing, Day 46 ±2, and at early termination. Definition of out-of-range: PR Interval \>210 milliseconds (msec); QRS \> 120 msec, QT \> 500 msec or \> 30 msec change from baseline (Day 1); QT with Fridericia correction (QTcF) \> 450 msec or change from baseline of \> 30 msec to \<= 60 msec or change from baseline \> 60 msec.
Time frame: Day 1 to Day 46 ±2 days or at early termination
Mean Change From Baseline in Sitting Systolic and Diastolic Blood Pressure - All Treated Participants
Systolic and Diastolic blood pressures were taken after the participant had been sitting quietly for at least 5 minutes and the pressures were measured in millimeters of mercury (mm Hg). Pressures were obtained at screening visit, Day -1, and at 0 hour (pre-dose), 0.5 hour (post dose), and 2 hours (post dose) on Days 1, 4, 7, 11. Baseline was defined as last non-missing result with a collection date-time less than the date-time of the first active dose of study drug.
Time frame: Baseline and 0.5 and 2.0 hours Post Dose on Days 1, 4, 7, and 11
Mean Change From Baseline in Sitting Heart Rate - All Treated Participants
Heart Rate was taken after the participant had been sitting quietly for at least 5 minutes and the heart rate was measured in beats per minute (bpm). Heart Rates were obtained at screening visit, Day -1, and at 0 hour (pre-dose), 0.5 hour (post dose), and 2 hours (post dose) on Days 1, 4, 7, 11. Baseline was defined as last non-missing result with a collection date-time less than the date-time of the first active dose of study drug.
Time frame: Baseline and 0.5 and 2.0 hours Post Dose on Days 1, 4, 7, and 11
Mean Change From Baseline in Systolic and Diastolic Blood Pressure at Study Discharge (Day 46±2 Days)
Systolic and Diastolic blood pressures were taken after the participant had been sitting quietly for at least 5 minutes and the pressures were measured in millimeters of mercury (mm Hg). Systolic and Diastolic blood pressures were taken on Day 46 (day of discharge from the study). Baseline was defined as last non-missing result with a collection date-time less than the date-time of the first active dose of study drug.
Time frame: Baseline and Day 46 ±2 days
Mean Change From Baseline in Heart Rate at Study Discharge (Day 46±2 Days)
Heart Rate was taken after the participant had been sitting quietly for at least 5 minutes and was measured in beats per minute (bpm). Hear rate was taken on Day 46 (day of discharge) during the follow up period. Baseline was defined as last non-missing result with a collection date-time less than the date-time of the first active dose of study drug.
Time frame: Baseline and Day 46 ±2 days
Study initiated January 2013 and completed April 2013. Participants (healthy volunteers) checked into a clinical pharmacology unit (CPU) on Day -1 for screening.
| Milestone | Inje Cocktail Alone and Inje Cocktail Plus Belatacept |
|---|---|
| Started | 22 |
| Completed | 18 |
| Not completed | 4 |
| Withdrew: Adverse event | 1 |
| Withdrew: Lost to follow-up | 1 |
| Withdrew: Withdrawal by subject | 2 |
Samples for the assessment of plasma concentrations of Inje cocktail components (midazolam, losartan, omeprazole, dextromethorphan and caffeine) and their metabolites (1'-hydroxy-midazolam, E-3174, 5-hydroxyomeprazole, dextrorphan, and paraxanthine) were collected at time = 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, and 24 hours relative to the dosing of belatacept on Day 4 and Inje cocktail dosing on Days 1, 4, 7, and 11, respectively. Adjusted geometric mean for midazolam with and without belatacept, along with adjusted geometric mean ratios for Days 4, 7, and 11 versus Day 1, respectively, are presented. Cmax measured in nanograms per milliliter (ng/mL). Inje cocktail components (Midazolam) measured using High Performance Liquid Chromatography (HPLC) with Tandem Mass Spectrometry (MS/MS) Detection.
| ng/mL | Day 1 Inje Cocktail | Day 4 Inje Cocktail Plus Belatacept | Day 7 Inje Cocktail | Day 11 Inje Cocktail |
|---|---|---|---|---|
| Adjusted Geometric Mean Maximum Drug Concentration (Cmax) of Midazolam With and Without the Coadministration of Belatacept - Pharmacokinetic (PK) Evaluable Population | 24.376 ± 42 | 24.152 (20.632 to 28.271) | 22.211 (19.131 to 25.787) | 24.220 (20.835 to 28.154) |
Samples for assessment of plasma concentrations of Inje cocktail components (midazolam, losartan, omeprazole, dextromethorphan and caffeine) were collected at time = 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, and 24 hours relative to the dosing of belatacept on Day 4 and Inje cocktail dosing on Days 1, 4, 7, and 11, respectively. The poor metabolizer of CYP2D6 was excluded from summary of dextromethorphan parameters. Inje cocktail components were each measured using HPLC with MS/MS detection. Tmax was measured in hours (h).
| h | Day 1 Inje Cocktail | Day 4 Inje Cocktail Plus Belatacept | Day 7 Inje Cocktail | Day 11 Inje Cocktail |
|---|---|---|---|---|
| Midazolam (N=22,21,21,20) | 0.50 (0.50 to 1.50) | 0.50 (0.50 to 1.50) | 0.50 (0.50 to 1.50) | 1.0 (0.50 to 1.03) |
| Losartan (N= 22, 21, 21, 20) | 1.52 (0.50 to 3.00) | 2.00 (0.50 to 4.00) | 1.50 (0.50 to 3.00) | 1.50 (0.50 to 3.00) |
| Omeprazole (N=22,21,21,20) | 2.00 (1.50 to 4.00) | 3.00 (1.00 to 8.05) | 3.00 (1.00 to 5.00) | 3.00 (1.00 to 12.00) |
| Dextromethorphan (N=21, 19, 19, 19) | 3.00 (1.00 to 6.00) | 3.00 (1.50 to 6.00) | 3.00 (1.50 to 5.15) | 3.00 (1.00 to 6.00) |
| Caffeine (N= 22,21,21,18) | 1.00 (0.50 to 2.00) | 1.00 (0.50 to 3.00) | 1.50 (0.50 to 4.00) | 1.50 (0.50 to 2.00) |
Samples for assessment of plasma concentrations of Inje cocktail components (midazolam, losartan, omeprazole, dextromethorphan and caffeine) were collected at time = 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, and 24 hours relative to the dosing of belatacept on Day 4 and Inje cocktail dosing on Days 1, 4, 7, and 11, respectively. The poor metabolizer of CYP2D6 was excluded from summary of dextromethorphan parameters. Inje cocktail components were each measured using HPLC with MS/MS detection. T-HALF was measured in hours (h).
| h | Day 1 Inje Cocktail | Day 4 Inje Cocktail Plus Belatacept | Day 7 Inje Cocktail | Day 11 Inje Cocktail |
|---|---|---|---|---|
| Midazolam (N=22, 21, 21, 20) | 4.01 ± 1.86 | 4.43 ± 1.89 | 4.27 ± 1.88 | 4.05 ± 1.61 |
| Losartan (N=22, 21, 21, 20) | 2.96 ± 1.29 | 2.56 ± 1.31 | 3.30 ± 1.49 | 2.87 ± 1.52 |
| Omeprazole (N= 22, 19, 21, 18) | 1.19 ± 0.497 | 1.39 ± 0.569 | 1.28 ± 0.470 | 1.36 ± 0.907 |
| Dextromethorphan (N=18, 17, 18, 15) | 6.76 ± 2.09 | 6.98 ± 2.67 | 6.33 ± 1.69 | 6.70 ± 2.29 |
| Caffeine (N=22, 21, 21, 18) | 5.61 ± 1.87 | 5.71 ± 2.01 | 6.17 ± 2.29 | 6.03 ± 2.13 |
Samples for assessment of plasma concentrations of Inje cocktail components (midazolam, losartan, omeprazole, dextromethorphan and caffeine) were collected at time = 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, and 24 hours relative to the dosing of belatacept on Day 4 and Inje cocktail dosing on Days 1, 4, 7, and 11, respectively. The poor metabolizer of CYP2D6 was excluded from summary of dextromethorphan parameters. Inje cocktail components were each measured using HPLC with MS/MS detection. CLT/F was measured as liters/hour (L/h)
| L/h | Day 1 Inje Cocktail | Day 4 Inje Cocktail Plus Belatacept | Day 7 Inje Cocktail | Day 11 Inje Cocktail |
|---|---|---|---|---|
| Midazolam (N=22, 21, 21, 20) | 73.8 ± 49 | 71.3 ± 48 | 77.3 ± 50 | 71.4 ± 51 |
| Losartan (N=22, 21, 21, 20) | 148 ± 37 | 146 ± 36 | 146 ± 34 | 151 ± 44 |
| Omeprazole (N=22, 19, 21, 18) | 29.2 ± 66 | 23.7 ± 72 | 24.7 ± 79 | 25.3 ± 69 |
| Dextromethorphan (N=18,17,18,18) | 3916 ± 85 | 4247 ± 84 | 4264 ± 126 | 3968 ± 107 |
| Caffeine (N=22, 21, 21, 18) | 4.99 ± 34 | 5.30 ± 32 | 4.97 ± 36 | 4.83 ± 36 |
Samples for assessment of plasma concentrations of Inje cocktail component metabolites (1'-hydroxy-midazolam, E-3174, 5-hydroxyomeprazole, dextrorphan, and paraxanthine) were collected at time = 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, and 24 hours relative to the dosing of belatacept on Day 4 and Inje cocktail dosing on Days 1, 4, 7, and 11, respectively. The poor metabolizer of CYP2D6 was excluded from summary of Dextrorphan parameters. Inje cocktail component metabolites were each measured using HPLC with MS/MS detection. Cmax was measured in ng/mL.
| ng/mL | Day 1 Inje Cocktail | Day 4 Inje Cocktail Plus Belatacept | Day 7 Inje Cocktail | Day 11 Inje Cocktail |
|---|---|---|---|---|
| 1'-Hydroxy-Midazolam (N=22, 21, 21, 20) | 11.1 ± 40 | 11.9 ± 40 | 11.4 ± 38 | 12.3 ± 36 |
| E-3174 (N=22, 21, 21, 20) | 262 ± 37 | 276 ± 33 | 300 ± 33 | 291 ± 41 |
| 5-Hydroxyomeprazole (N=22, 21, 21, 20) | 335 ± 41 | 360 ± 40 | 332 ± 38 | 337 ± 38 |
| Dextrorphan (N=21,20,20,19) | 342 ± 30 | 324 ± 32 | 312 ± 31 | 331 ± 35 |
| Paraxanthine (N=17,19,18,18) | 1291 ± 15 | 1367 ± 12 | 1320 ± 13 | 1358 ± 15 |
Area under the plasma concentration-time curve from zero to the last time of the last quantifiable concentration \[AUC(0-T)\] was measured in ng\*h/mL. Samples for assessment of plasma concentrations of Inje cocktail components metabolites (1'-hydroxy-midazolam, E-3174, 5-hydroxyomeprazole, dextrorphan, and paraxanthine) were collected at time = 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, and 24 hours relative to the dosing of belatacept on Day 4 and Inje cocktail dosing on Days 1, 4, 7, and 11, respectively. The poor metabolizer of CYP2D6 was excluded from summary of Dextrorphan parameters. Inje cocktail components were each measured using HPLC with MS/MS detection.
| ng*h/mL | Day 1 Inje Cocktail | Day 4 Inje Cocktail Plus Belatacept | Day 7 Inje Cocktail | Day 11 Inje Cocktail |
|---|---|---|---|---|
| 1'-hydroxy-midazolam (N=22, 21, 21, 20) | 28.9 ± 39 | 31.8 ± 30 | 32.5 ± 32 | 33.6 ± 27 |
| E-3174 (N= 22,21,21,20) | 1995 ± 32 | 1999 ± 29 | 2089 ± 30 | 2072 ± 37 |
| 5-hydroxyomeprazole (N=22,21,21,20) | 997 ± 36 | 967 ± 33 | 929 ± 35 | 995 ± 35 |
| dextrorphan (N=21,20,20,19) | 1636 ± 27 | 1570 ± 26 | 1519 ± 27 | 1644 ± 26 |
| paraxanthine (N=17,19,18,18) | 20592 ± 15 | 21077 ± 16 | 20680 ± 18 | 21353 ± 20 |
Area under the plasma concentration-time curve from time zero extrapolated to infinite time \[AUC(INF)\] was measured in ng\*h/mL. Samples for assessment of plasma concentrations of Inje cocktail components metabolites (1'-hydroxy-midazolam, E-3174, 5-hydroxyomeprazole, dextrorphan, and paraxanthine) were collected at time = 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, and 24 hours relative to the dosing of belatacept on Day 4 and Inje cocktail dosing on Days 1, 4, 7, and 11, respectively. The poor metabolizer of CYP2D6 was excluded from summary of Dextrorphan parameters. Inje cocktail components were each measured using HPLC with MS/MS detection.
| ng*h/mL | Day 1 Inje Cocktail | Day 4 Inje Cocktail Plus Belatacept | Day 7 Inje Cocktail | Day 11 Inje Cocktail |
|---|---|---|---|---|
| 1'-hydroxy-midazolam (N=22,21,20,20) | 30.5 ± 38 | 33.8 ± 32 | 32.9 ± 27 | 35.1 ± 27 |
| E-3174 (N=22,20,21,20) | 2103 ± 32 | 2060 ± 29 | 2187 ± 31 | 2182 ± 38 |
| 5-hydroxyomeprazole (N=22,20,21,17 | 1010 ± 36 | 990 ± 34 | 938 ± 35 | 1063 ± 32 |
| dextrorphan (N=21,20,20,19) | 1679 ± 25 | 1610 ± 25 | 1562 ± 26 | 1682 ± 25 |
| paraxanthine (N=7,8,6,6) | 22401 ± 18 | 22905 ± 24 | 22063 ± 12 | 21874 ± 20 |
Samples for assessment of plasma concentrations of Inje cocktail components metabolites (1'-hydroxy-midazolam, E-3174, 5-hydroxyomeprazole, dextrorphan, and paraxanthine) were collected at time = 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, and 24 hours relative to the dosing of belatacept on Day 4 and Inje cocktail dosing on Days 1, 4, 7, and 11, respectively. The poor metabolizer of CYP2D6 was excluded from summary of Dextrorphan parameters. Inje cocktail components were each measured using HPLC with MS/MS detection. Time of maximum observed plasma concentration (Tmax) was measured in hours (h).
| h | Day 1 Inje Cocktail | Day 4 Inje Cocktail Plus Belatacept | Day 7 Inje Cocktail | Day 11 Inje Cocktail |
|---|---|---|---|---|
| 1'-Hydroxy-Midazolam (N=22,21,21,20) | 1.00 (0.50 to 1.50) | 1.00 (0.50 to 2.00) | 1.00 (0.50 to 1.50) | 1.00 (0.50 to 1.50) |
| E-3174 (N=22, 21, 21, 20) | 4.00 (3.00 to 5.03) | 4.00 (2.00 to 8.00) | 4.00 (3.00 to 5.15) | 4.00 (3.00 to 6.02) |
| 5-Hydroxyomeprazole (N=22,21,21,20) | 2.00 (1.50 to 5.00) | 3.00 (1.00 to 8.05) | 3.00 (1.00 to 5.00) | 2.53 (1.00 to 12.00) |
| Dextrorphan (N=21,20,20,19) | 2.00 (1.50 to 4.00) | 2.00 (1.50 to 4.00) | 2.00 (1.50 to 3.00) | 2.00 (1.50 to 4.00) |
| Paraxanthine (N=17, 19, 18, 18) | 8.00 (3.00 to 12.02) | 8.00 (5.00 to 12.00) | 8.00 (4.0 to 12.00) | 8.00 (4.00 to 12.00) |
Plasma half-life (T-HALF) was measured in hours (h). Samples for assessment of plasma concentrations of Inje cocktail components metabolites (1'-hydroxy-midazolam, E-3174, 5-hydroxyomeprazole, dextrorphan, and paraxanthine) were collected at time = 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, and 24 hours relative to the dosing of belatacept on Day 4 and Inje cocktail dosing on Days 1, 4, 7, and 11, respectively. The poor metabolizer of CYP2D6 was excluded from summary of Dextrorphan parameters. Inje cocktail components were each measured using HPLC with MS/MS detection.
| h | Day 1 Inje Cocktail | Day 4 Inje Cocktail Plus Belatacept | Day 7 Inje Cocktail | Day 11 Inje Cocktail |
|---|---|---|---|---|
| 1'-Hydroxy-Midazolam (N=22,21,20,20) | 5.29 ± 2.98 | 6.35 ± 3.60 | 5.61 ± 3.47 | 5.31 ± 2.65 |
| E-3174 (N=22, 20, 21, 20) | 4.86 ± 0.749 | 4.57 ± 0.757 | 4.75 ± 0.757 | 4.88 ± 0.690 |
| 5-Hydroxyomeprazole (N=22,20,21,17) | 1.43 ± 0.308 | 1.55 ± 0.397 | 1.52 ± 0.371 | 1.54 ± 0.624 |
| Dextrorphan (N=21,20,20,19) | 4.26 ± 1.60 | 4.36 ± 1.46 | 4.23 ± 1.13 | 4.08 ± 0.999 |
| Paraxanthine (N=7,8,6,6) | 7.33 ± 1.91 | 6.86 ± 1.71 | 7.33 ± 1.55 | 7.44 ± 2.67 |
Metabolite (paraxanthine) to parent (caffeine) ratio was corrected for molecular weight. AUC (0-T) and AUC (INF) measured in ng\*h/mL. Samples for assessment of plasma concentrations of Inje cocktail components and the metabolites of those components were collected at time = 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, and 24 hours relative to the dosing of belatacept on Day 4 and Inje cocktail dosing on Days 1, 4, 7, and 11, respectively. Inje cocktail components were each measured using HPLC with MS/MS detection.
| ratio | Day 1 Inje Cocktail | Day 4 Inje Cocktail Plus Belatacept | Day 7 Inje Cocktail | Day 11 Inje Cocktail |
|---|---|---|---|---|
| MR_AUC(0-T) ratio; N=17,19,18,18 | 0.627 ± 24 | 0.677 ± 17 | 0.635 ± 20 | 0.603 ± 21 |
| MR_AUC(INF) ratio; N=7, 8, 6, 6 | 0.827 ± 15 | 0.827 ± 8 | 0.799 ± 14 | 0.781 ± 12 |
Metabolite (paraxanthine) to parent (caffeine) ratio was corrected for molecular weight. Cmax measured in ng/mL. Samples for assessment of plasma concentrations of Inje cocktail components and their metabolites were collected at time = 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, and 24 hours relative to the dosing of belatacept on Day 4 and Inje cocktail dosing on Days 1, 4, 7, and 11, respectively. Inje cocktail components were each measured using HPLC with MS/MS detection.
| ratio | Day 1 Inje Cocktail | Day 4 Inje Cocktail Plus Belatacept | Day 7 Inje Cocktail | Day 11 Inje Cocktail |
|---|---|---|---|---|
| Ratio of Paraxanthine (Cmax) to Caffeine (Cmax), Corrected for Molecular Weight (MR_Cmax) With and Without Coadministration of Belatacept - PK Evaluable Population | 0.303 ± 22 | 0.337 ± 15 | 0.333 ± 23 | 0.323 ± 20 |
Metabolite (E-3174) to parent (losartan) ratio was corrected for molecular weight. AUC (0-T) and AUC (INF) measured in ng\*h/mL. Samples for assessment of plasma concentrations of Inje cocktail components and the metabolites of those components were collected at time = 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, and 24 hours relative to the dosing of belatacept on Day 4 and Inje cocktail dosing on Days 1, 4, 7, and 11, respectively. Inje cocktail components were each measured using HPLC with MS/MS detection.
| ratio | Day 1 Inje Cocktail | Day 4 Inje Cocktail Plus Belatacept | Day 7 Inje Cocktail | Day 11 Inje Cocktail |
|---|---|---|---|---|
| MR_AUC (0-T) ratio; N=22,21,21,20 | 5.81 ± 32 | 5.75 ± 33 | 5.99 ± 33 | 6.17 ± 33 |
| MR_AUC (INF) ratio; N=22,20,21,20 | 6.02 ± 30 | 5.99 ± 32 | 6.16 ± 32 | 6.37 ± 31 |
Metabolite (E-3174) to parent (losartan) ratio was corrected for molecular weight. Cmax measured in ng/mL. Samples for assessment of plasma concentrations of Inje cocktail components and the metabolites of those components were collected at time = 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, and 24 hours relative to the dosing of belatacept on Day 4 and Inje cocktail dosing on Days 1, 4, 7, and 11, respectively. Inje cocktail components were each measured using HPLC with MS/MS detection.
| ratio | Day 1 Inje Cocktail | Day 4 Inje Cocktail Plus Belatacept | Day 7 Inje Cocktail | Day 11 Inje Cocktail |
|---|---|---|---|---|
| Ratio of E-3174 (Cmax) to Losartan (Cmax), Corrected for Molecular Weight (MR_Cmax) With and Without Coadministration of Belatacept - PK Evaluable Population | 2.31 ± 39 | 2.24 ± 45 | 2.26 ± 43 | 2.26 ± 45 |
Metabolite (5-Hydroxyomeprazole) to parent (omeprazole) ratio was corrected for molecular weight. AUC (0-T) and AUC (INF) measured in ng\*h/mL. Samples for assessment of plasma concentrations of Inje cocktail components and the metabolites of those components were collected at time = 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, and 24 hours relative to the dosing of belatacept on Day 4 and Inje cocktail dosing on Days 1, 4, 7, and 11, respectively. Inje cocktail components were each measured using HPLC with MS/MS detection.
| ratio | Day 1 Inje Cocktail | Day 4 Inje Cocktail Plus Belatacept | Day 7 Inje Cocktail | Day 11 Inje Cocktail |
|---|---|---|---|---|
| MR_AUC (0-T) ratio; N=22,21,21,20 | 0.700 ± 57 | 0.609 ± 66 | 0.551 ± 70 | 0.610 ± 66 |
| MR_AUC (INF) ratio; N=22,19,21,17 | 0.705 ± 56 | 0.558 ± 61 | 0.553 ± 69 | 0.679 ± 62 |
Metabolite (5-hydroxyomeprazole) to parent (omeprazole) ratio was corrected for molecular weight. Cmax measured in ng/mL. Samples for assessment of plasma concentrations of Inje cocktail components and the metabolites of those components were collected at time = 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, and 24 hours relative to the dosing of belatacept on Day 4 and Inje cocktail dosing on Days 1, 4, 7, and 11, respectively. Inje cocktail components were each measured using HPLC with MS/MS detection.
| ratio | Day 1 Inje Cocktail | Day 4 Inje Cocktail Plus Belatacept | Day 7 Inje Cocktail | Day 11 Inje Cocktail |
|---|---|---|---|---|
| Ratio of 5-Hydroxyomeprazole (Cmax) to Omeprazole (Cmax), Corrected for Molecular Weight (MR_Cmax) With and Without Coadministration of Belatacept - PK Evaluable Population | 0.548 ± 54 | 0.471 ± 60 | 0.424 ± 65 | 0.478 ± 59 |
Metabolite (5-dextrorphan ) to parent (dextromethorphan) ratio was corrected for molecular weight. AUC (0-T) and AUC (INF) measured in ng\*h/mL. Samples for assessment of plasma concentrations of Inje cocktail components and the metabolites of those components were collected at time = 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, and 24 hours relative to the dosing of belatacept on Day 4 and Inje cocktail dosing on Days 1, 4, 7, and 11, respectively. The poor metabolizer of CYP2D6 was excluded from summary of Dextrorphan parameters. Inje cocktail components were each measured using HPLC with MS/MS detection.
| ratio | Day 1 Inje Cocktail | Day 4 Inje Cocktail Plus Belatacept | Day 7 Inje Cocktail | Day 11 Inje Cocktail |
|---|---|---|---|---|
| MR_AUC (0-T) ratio; N=21,20,20,19 | 201 ± 103 | 200 ± 94 | 177 ± 124 | 193 ± 99 |
| MR_AUC (INF) ratio; N=18,17,18,15 | 173 ± 95 | 177 ± 90 | 170 ± 122 | 173 ± 102 |
Metabolite (5-dextrorphan) to parent (dextromethorphan) ratio was corrected for molecular weight. Cmax measured in ng/mL. Samples for assessment of plasma concentrations of Inje cocktail components and the metabolites of those components were collected at time = 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, and 24 hours relative to the dosing of belatacept on Day 4 and Inje cocktail dosing on Days 1, 4, 7, and 11, respectively. The poor metabolizer of CYP2D6 was excluded from summary of Dextrorphan parameters. Inje cocktail components were each measured using HPLC with MS/MS detection.
| ratio | Day 1 Inje Cocktail | Day 4 Inje Cocktail Plus Belatacept | Day 7 Inje Cocktail | Day 11 Inje Cocktail |
|---|---|---|---|---|
| Ratio of 5-Dextrorphan (Cmax) to Dextromethorphan (Cmax), Corrected for Molecular Weight (MR_Cmax) With and Without Coadministration of Belatacept - PK Evaluable Population | 280 ± 107 | 303 ± 99 | 275 ± 88 | 303 ± 84 |
Metabolite (1'-hydroxy-midazolam) to parent (midazolam) ratio was corrected for molecular weight. AUC (0-T) and AUC (INF) measured in ng\*h/mL. Samples for assessment of plasma concentrations of Inje cocktail components and the metabolites of those components were collected at time = 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, and 24 hours relative to the dosing of belatacept on Day 4 and Inje cocktail dosing on Days 1, 4, 7, and 11, respectively. Inje cocktail components were each measured using HPLC with MS/MS detection.
| ratio | Day 1 Inje Cocktail | Day 4 Inje Cocktail Plus Belatacept | Day 7 Inje Cocktail | Day 11 Inje Cocktail |
|---|---|---|---|---|
| MR_AUC (0-T) ratio; N=22, 21, 21, 20 | 0.421 ± 56 | 0.447 ± 46 | 0.495 ± 55 | 0.472 ± 55 |
| MR_(INF) ratio; N=22, 21, 20, 20 | 0.428 ± 57 | 0.460 ± 47 | 0.479 ± 52 | 0.478 ± 55 |
AUC(0-T): area under the plasma concentration-time curve from zero to the last time of the last quantifiable concentration and AUC (INF): AUC from time zero extrapolated to infinite time were measured in ng\*h/mL. Samples for the assessment of plasma concentrations of Inje cocktail components (midazolam, losartan, omeprazole, dextromethorphan and caffeine) and their metabolites (1'-hydroxy-midazolam, E-3174, 5-hydroxyomeprazole, dextrorphan, and paraxanthine) were collected at time = 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, and 24 hours relative to the dosing of belatacept on Day 4 and Inje cocktail dosing on Days 1, 4, 7, and 11, respectively. Adjusted geometric mean for midazolam with and without belatacept, along with adjusted geometric mean ratios for Days 4, 7, and 11 versus Day 1, respectively, are presented. Midazolam measured using HPLC with MS/MS Detection.
| ng*h/mL | Day 1 Inje Cocktail | Day 4 Inje Cocktail Plus Belatacept | Day 7 Inje Cocktail | Day 11 Inje Cocktail |
|---|---|---|---|---|
| AUC (0-T);N=22, 21, 21, 20) | 65.548 (53.271 to 80.655) | 68.833 (57.008 to 83.111) | 63.303 (52.240 to 76.707) | 67.717 (56.128 to 81.697) |
| AUC (INF);N=22, 21, 21, 20) | 67.743 (54.839 to 83.683) | 71.039 (58.555 to 86.186) | 65.555 (54.019 to 79.554) | 69.841 (57.771 to 84.433) |
Cmax measured in ng/mL. Samples for assessment of plasma concentrations of Inje cocktail components (midazolam, losartan, omeprazole, dextromethorphan and caffeine) and their metabolites (1'-hydroxy-midazolam, E-3174, 5-hydroxyomeprazole, dextrorphan, and paraxanthine) were collected at time = 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, and 24 hours relative to the dosing of belatacept on Day 4 and Inje cocktail dosing on Days 1, 4, 7, and 11, respectively. Adjusted geometric mean for losartan with and without belatacept, along with adjusted geometric mean ratios for Days 4, 7, and 11 versus Day 1, respectively, are presented. Inje cocktail components (losartan) measured using HPLC with MS/MS Detection.
| ng/mL | Day 1 Inje Cocktail | Day 4 Inje Cocktail Plus Belatacept | Day 7 Inje Cocktail | Day 11 Inje Cocktail |
|---|---|---|---|---|
| Adjusted Geometric Mean Cmax of Losartan With and Without the Coadministration of Belatacept - PK Evaluable Population | 119.789 (89.629 to 134.485) | 118.663 (97.209 to 144.850) | 127.184 (105.467 to 153.373) | 126.461 (101.676 to 157.288) |
AUC (0-T): area under the concentration curve from time 0 to the time of the last quantifiable concentration and AUC (INF) extrapolated to infinity were measured in ng\*h/mL. Samples for assessment of plasma concentrations of Inje cocktail components (midazolam, losartan, omeprazole, dextromethorphan and caffeine) and their metabolites (1'-hydroxy-midazolam, E-3174, 5-hydroxyomeprazole, dextrorphan, and paraxanthine) were collected at time = 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, and 24 hours relative to the dosing of belatacept on Day 4 and Inje cocktail dosing on Days 1, 4, 7, and 11, respectively. Adjusted geometric mean for losartan with and without belatacept, along with adjusted geometric mean ratios for Days 4, 7, and 11 versus Day 1, respectively, are presented. Inje cocktail components (losartan) measured using HPLC with MS/MS Detection.
| ng*h/mL | Day 1 Inje Cocktail | Day 4 Inje Cocktail Plus Belatacept | Day 7 Inje Cocktail | Day 11 Inje Cocktail |
|---|---|---|---|---|
| AUC (0-T) N=22, 21, 21, 20) | 332.191 (283.753 to 388.898) | 336.531 (291.278 to 388.815) | 337.487 (295.482 to 385.462) | 332.400 (280.799 to 393.484) |
| AUC (INF) N=22, 21, 21, 20) | 338.033 (289.143 to 395.189) | 341.644 (296.237 to 394.012) | 343.508 (301.494 to 391.378) | 338.646 (286.824 to 399.831) |
Cmax: Maximum observed plasma concentration was measured in ng/mL. Samples for assessment of plasma concentrations of Inje cocktail components (midazolam, losartan, omeprazole, dextromethorphan and caffeine) and their metabolites (1'-hydroxy-midazolam, E-3174, 5-hydroxyomeprazole, dextrorphan, and paraxanthine) were collected at time = 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, and 24 hours relative to the dosing of belatacept on Day 4 and Inje cocktail dosing on Days 1, 4, 7, and 11, respectively. Adjusted geometric mean for omeprazole with and without belatacept, along with adjusted geometric mean ratios for Days 4, 7, and 11 versus Day 1, respectively, are presented. Inje cocktail components (omeprazole) measured using HPLC with MS/MS Detection.
| ng/mL | Day 1 Inje Cocktail | Day 4 Inje Cocktail Plus Belatacept | Day 7 Inje Cocktail | Day 11 Inje Cocktail |
|---|---|---|---|---|
| Adjusted Geometric Mean Cmax of Omeprazole With and Without the Coadministration of Belatacept - Pharmacokinetic (PK) Evaluable Population | 583.047 (473.091 to 718.560) | 734.776 (587.280 to 919.316) | 753.126 (597.946 to 948.579) | 686.929 (555.590 to 849.315) |
AUC(0-T): Area under the plasma concentration-time curve from time zero zero to the time of the last quantifiable concentration and AUC (INF): AUC extrapolated to infinity were measured in ng\*h/mL. Samples for assessment of plasma concentrations of Inje cocktail components (midazolam, losartan, omeprazole, dextromethorphan and caffeine) and their metabolites (1'-hydroxy-midazolam, E-3174, 5-hydroxyomeprazole, dextrorphan, and paraxanthine) were collected at time = 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, and 24 hours relative to the dosing of belatacept on Day 4 and Inje cocktail dosing on Days 1, 4, 7, and 11, respectively. Adjusted geometric mean for omeprazole with and without belatacept, along with adjusted geometric mean ratios for Days 4, 7, and 11 versus Day 1, respectively, are presented. Inje cocktail components (omeprazole) measured using HPLC with MS/MS Detection.
| ng*h/mL | Day 1 Inje Cocktail | Day 4 Inje Cocktail Plus Belatacept | Day 7 Inje Cocktail | Day 11 Inje Cocktail |
|---|---|---|---|---|
| AUC (0-T); (N= 22, 21, 21, 20) | 1361.024 (1066.457 to 1736.953) | 1577.017 (1200.238 to 2072.075) | 1671.173 (1278.936 to 2183.704) | 1653.491 (1264.315 to 2162.463) |
| AUC (INF); (N= 22, 19, 21, 18) | 1368.593 (1072.836 to 1745.885) | 1632.455 (1251.956 to 2128.597) | 1679.693 (1286.299 to 2193.400) | 1779.717 (1380.250 to 2294.798) |
Cmax was measured in ng/mL. Samples for assessment of plasma concentrations of Inje cocktail components (midazolam, losartan, omeprazole, dextromethorphan and caffeine) and their metabolites (1'-hydroxy-midazolam, E-3174, 5-hydroxyomeprazole, dextrorphan, and paraxanthine) were collected at time = 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, and 24 hours relative to the dosing of belatacept on Day 4 and Inje cocktail dosing on Days 1, 4, 7, and 11, respectively. Adjusted geometric mean for dextromethorphan with and without belatacept, along with adjusted geometric mean ratios for Days 4, 7, and 11 versus Day 1, respectively, are presented. The poor metabolizer of CYP2D6 was excluded from the statistical analysis. Inje cocktail components (dextromethorphan) measured using HPLC with MS/MS Detection.
| ng/mL | Day 1 Inje Cocktail | Day 4 Inje Cocktail Plus Belatacept | Day 7 Inje Cocktail | Day 11 Inje Cocktail |
|---|---|---|---|---|
| Adjusted Geometric Mean Cmax of Dextromethorphan With and Without the Coadministration of Belatacept - PK Evaluable Population | 0.927 (0.566 to 1.518) | 0.800 (0.512 to 1.250) | 0.855 (0.553 to 1.320) | 0.794 (0.490 to 1.286) |
AUC(0-T): area under the plasma concentration-time curve from time zero to the time of the last quantifiable concentration and AUC (INF): AUC extrapolated to infinity, were measured as ng\*h/mL. Samples for assessment of plasma concentrations of Inje cocktail components (midazolam, losartan, omeprazole, dextromethorphan and caffeine) and their metabolites (1'-hydroxy-midazolam, E-3174, 5-hydroxyomeprazole, dextrorphan, and paraxanthine) were collected at time = 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, and 24 hours relative to the dosing of belatacept on Day 4 and Inje cocktail dosing on Days 1, 4, 7, and 11, respectively. Adjusted geometric mean for dextromethorphan with and without belatacept, along with adjusted geometric mean ratios for Days 4, 7, and 11 versus Day 1, respectively, are presented. The poor metabolizer of CYP2D6 was excluded from the statistical analysis. Inje cocktail components (dextromethorphan) measured using HPLC with MS/MS Detection.
| ng*h/mL | Day 1 Inje Cocktail | Day 4 Inje Cocktail Plus Belatacept | Day 7 Inje Cocktail | Day 11 Inje Cocktail |
|---|---|---|---|---|
| AUC (0-T); N= 21, 19, 19, 19 | 6.176 (3.466 to 11.005) | 5.651 (3.305 to 9.661) | 6.195 (3.705 to 10.358) | 5.949 (3.465 to 10.215) |
| AUC (INF); N= 18, 17, 18, 15 | 6.220 (3.743 to 10.337) | 5.455 (3.372 to 8.825) | 6.412 (4.200 to 9.790) | 6.359 (1.143 to 9.760) |
Samples for assessment of plasma concentrations of Inje cocktail components (midazolam, losartan, omeprazole, dextromethorphan and caffeine) were collected at time = 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, and 24 hours relative to the dosing of belatacept on Day 4 and Inje cocktail dosing on Days 1, 4, 7, and 11, respectively. Inje cocktail components were each measured using HPLC with MS/MS detection. Cmax was measured in ng/mL.
| ng/mL | Day 1 Inje Cocktail | Day 4 Inje Cocktail Plus Belatacept | Day 7 Inje Cocktail | Day 11 Inje Cocktail |
|---|---|---|---|---|
| Adjusted Geometric Mean Cmax of Caffeine With and Without the Coadministration of Belatacept - PK Evaluable Population | 4696.505 (4252.803 to 5186.499) | 4450.019 (4172.484 to 4746.014) | 4332.326 (3993.257 to 4700.186) | 4479.687 (4141.210 to 4845.830) |
Samples for assessment of plasma concentrations of Inje cocktail components (midazolam, losartan, omeprazole, dextromethorphan and caffeine) were collected at time = 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, and 24 hours relative to the dosing of belatacept on Day 4 and Inje cocktail dosing on Days 1, 4, 7, and 11, respectively. Inje cocktail components were each measured using HPLC with MS/MS detection. AUC (0-T) and AUC (INF) were measured as ng\*h/mL.
| ng*h/mL | Day 1 Inje Cocktail | Day 4 Inje Cocktail Plus Belatacept | Day 7 Inje Cocktail | Day 11 Inje Cocktail |
|---|---|---|---|---|
| AUC (0-T); N= 22, 21, 21, 18 | 37394.5 (33103.4 to 42241.8) | 35200.3 (31255.9 to 39642.5) | 36853.4 (32319.8 to 42022.9) | 38407.0 (34164.2 to 43176.7) |
| AUC (INF); N= 22, 21, 21, 18 | 40084.1 (34881.6 to 46062.5) | 37647.8 (32705.5 to 43336.9) | 40149.9 (34434.3 to 46814.1) | 41537.6 (36092.9 to 47803.7) |
Metabolite (1'-hydroxy-midazolam) to parent (midazolam) ratio was corrected for molecular weight. Cmax measured in ng/mL. Samples for assessment of plasma concentrations of Inje cocktail components and the metabolites of those components were collected at time = 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, and 24 hours relative to the dosing of belatacept on Day 4 and Inje cocktail dosing on Days 1, 4, 7, and 11, respectively. Inje cocktail components were each measured using HPLC with MS/MS detection.
| ratio | Day 1 Inje Cocktail | Day 4 Inje Cocktail Plus Belatacept | Day 7 Inje Cocktail | Day 11 Inje Cocktail |
|---|---|---|---|---|
| Ratio of 1'-Hydroxy-Midazolam (Cmax) to Midazolam (Cmax), Corrected for Molecular Weight (MR_Cmax) With and Without Coadministration of Belatacept - PK Evaluable Population | 0.432 ± 45 | 0.476 ± 44 | 0.497 ± 46 | 0.490 ± 46 |
Adverse events were coded according to the Medical Dictionary for Regulatory Activities (MedDRA), version 15.1. AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Events captured from Day 1 (pre-dose) to last day prior to discharge (Day 46 ±2). In the total group, a participant with an AE is only counted once (ie, data reflected in Days 1, 4, 7, and 11 below could be the same participant with an AE on multiple days of the study).
| participants | Day 1 Inje Cocktail | Day 4 Inje Cocktail Plus Belatacept | Day 7 Inje Cocktail | Day 11 Inje Cocktail | All Participants |
|---|---|---|---|---|---|
| Adverse Events | 4 | 2 | 1 | 1 | 5 |
| SAEs | 0 | 0 | 0 | 0 | 0 |
| Deaths | 0 | 0 | 0 | 0 | 0 |
| AEs leading to discontinuation | 0 | 0 | 1 | 0 | 1 |
Samples for laboratory tests were obtained at Screening visit, Day -1 or prior to dosing on Day 1, Days 3, 6, 10, 46, and at early termination, after 10 hours fasting. Upper limits of normal (ULN); Lower limits of normal (LLN); Pre-therapy (Rx); micromoles per liter (µmol/L); millimoles per liter (mmol/L); grams per liter (g/L); Units per liter (U/L); Aspartate Aminotransferase (AST); Blood Urea Nitrogen (BUN) Total Bilirubin: \>1.1\*ULN if Pre-Rx\<= ULN or Pre-Rx is missing, or \>1.2\*Pre-Rx if Pre-Rx \>ULN. AST: \>1.25\*Pre-Rx if Pre-Rx \>ULN or 1.25\*ULN if Pre-Rx \<= ULN or Pre-Rx is missing. BUN: \>1.1\*ULN if Pre-Rx\<= ULN or Pre-Rx is missing, or \>1.2\*Pre-Rx if Pre-Rx \>ULN. Phosphorus: \<0.85\*LLN if Pre-RX \>= LLN or is missing or if Pre-Rx \< LLN. total Protein: \<0.9\*LLN if Pre-Rx\>= LLN or is missing or Pre-Rx \> LLN. Creatine Kinase: \>1.5\*Pre-Rx if Pre-Rx \> ULN or is missing or Pre-Rx is \<= ULN. Lactate Dehydrogenase: \>1.25\*ULN if Pre-Rx \<= ULN or missing, \>1.5\*Pre-Rx if Pre-Rx \> ULN.
| participants | Inje Cocktail Alone and Inje Cocktail Plus Belatacept |
|---|---|
| Total bilirubin >1.1*ULN µmol/L (N=22) | 1 |
| AST >1.25*Pre-Rx U/L (N=22) | 1 |
| BUN >1.1*ULN mmol/L (N=22) | 1 |
| Inorganic Phosphorus <0.85*LLN mmol/L (N=22) | 1 |
| Total Protein <0.9*LLN g/L (N=22) | 1 |
| Creatine Kinase > 1.5* Pre-Rx U/L (N=22) | 2 |
| Lactate Dehydrogenase >1.25*ULN U/L (N=22) | 1 |
Samples for laboratory tests were obtained at Screening visit, Day -1 or prior to dosing on Day 1, Days 3, 6, 10, 46 ±2, and at early termination, after 10 hours fasting. Leukocytes: \*10\^9 cells per liter (c/L) \< 0.85\*Pre-Rx if Pre-Rx \< LLN or \<0.9\*LLN if LLN \<= Pre-Rx or Pre-Rx is missing. Neutrophils (absolute): \*10\^12 c/L \< 0.85\* Pre-Rx if Pre-Rx \< 1.5, \<1.5 if Pre-Rx \>= 1.5, \< 1.5 if Pre-Rx missing. Urine blood from dipstick: \>=2 if Pre-Rx \<1 or was missing or if Pre-Rx \>=1. Urinary microscopic white blood cells (WBC) and red blood cells (RBC) \>= 2 if Pre-Rx \<2 or if Pre-Rx was missing or \>=4 if Pre-Rx \>=2.
| participants | Inje Cocktail Alone and Inje Cocktail Plus Belatacept |
|---|---|
| Leukocytes <0.85*Pre-Rx *10^9 c/L (N=22) | 1 |
| Neutrophils <0.85*Pre-Rx *10^12 c/L (N=22) | 4 |
| Urine Blood >= 2 (N=22) | 2 |
| Urinary RBC microscopic >= 2 (N=8) | 1 |
| Urinary WBC microscopic >= 2 (N=8) | 1 |
Participants had 12-Lead electrocardiograms (ECGs) performed at Screening Visit, Day 1 prior to dosing, Day 46 ±2, and at early termination. Definition of out-of-range: PR Interval \>210 milliseconds (msec); QRS \> 120 msec, QT \> 500 msec or \> 30 msec change from baseline (Day 1); QT with Fridericia correction (QTcF) \> 450 msec or change from baseline of \> 30 msec to \<= 60 msec or change from baseline \> 60 msec.
| participants | Inje Cocktail Alone and Inje Cocktail Plus Belatacept |
|---|---|
| Day 46 (N=18) | 0 |
| Early Termination (N=2) | 0 |
Systolic and Diastolic blood pressures were taken after the participant had been sitting quietly for at least 5 minutes and the pressures were measured in millimeters of mercury (mm Hg). Pressures were obtained at screening visit, Day -1, and at 0 hour (pre-dose), 0.5 hour (post dose), and 2 hours (post dose) on Days 1, 4, 7, 11. Baseline was defined as last non-missing result with a collection date-time less than the date-time of the first active dose of study drug.
| mm Hg | Day 1 Inje Cocktail | Day 4 Inje Cocktail Plus Belatacept | Day 7 Inje Cocktail | Day 11 Inje Cocktail |
|---|---|---|---|---|
| Systolic 0.5 hour post dose (N=22,21,21,20) | -0.6 ± 10.15 | 0.1 ± 12.81 | -4.9 ± 9.05 | -4.7 ± 10.13 |
| Systolic 2.0 hour post dose (N=22,21,21,20) | 0.2 ± 10.09 | 2.0 ± 11.79 | -2.7 ± 9.85 | -2.9 ± 11.73 |
| Diastolic 0.5 hour post dose (N=22,21,21,20) | -1.7 ± 6.52 | -0.2 ± 6.03 | -2.2 ± 7.54 | -2.2 ± 5.38 |
| Diastolic 2.0 hour post dose (N=22,21,21,20) | 0.9 ± 4.67 | -2.0 ± 4.53 | -3.4 ± 5.22 | -1.0 ± 5.83 |
Heart Rate was taken after the participant had been sitting quietly for at least 5 minutes and the heart rate was measured in beats per minute (bpm). Heart Rates were obtained at screening visit, Day -1, and at 0 hour (pre-dose), 0.5 hour (post dose), and 2 hours (post dose) on Days 1, 4, 7, 11. Baseline was defined as last non-missing result with a collection date-time less than the date-time of the first active dose of study drug.
| bpm | Day 1 Inje Cocktail | Day 4 Inje Cocktail Plus Belatacept | Day 7 Inje Cocktail | Day 11 Inje Cocktail |
|---|---|---|---|---|
| Heart Rate 0.5 hour post dose (N=22, 21, 21, 20) | -3.3 ± 12.38 | -4.2 ± 13.15 | -1.8 ± 12.58 | -1.6 ± 10.03 |
| Heart Rate 2.0 hour post dose (N=22, 21, 21, 20) | -3.5 ± 10.61 | 0.2 ± 13.86 | 0.5 ± 11.95 | 3.1 ± 11.91 |
Systolic and Diastolic blood pressures were taken after the participant had been sitting quietly for at least 5 minutes and the pressures were measured in millimeters of mercury (mm Hg). Systolic and Diastolic blood pressures were taken on Day 46 (day of discharge from the study). Baseline was defined as last non-missing result with a collection date-time less than the date-time of the first active dose of study drug.
| mm Hg | Post Treatment |
|---|---|
| Systolic (N=18) | -5.9 ± 11.25 |
| Diastolic (N=18) | -5.7 ± 8.87 |
Heart Rate was taken after the participant had been sitting quietly for at least 5 minutes and was measured in beats per minute (bpm). Hear rate was taken on Day 46 (day of discharge) during the follow up period. Baseline was defined as last non-missing result with a collection date-time less than the date-time of the first active dose of study drug.
| bpm | Post Treatment |
|---|---|
| Mean Change From Baseline in Heart Rate at Study Discharge (Day 46±2 Days) | 1.0 ± 15.86 |
Collected over Day 1 to Day of discharge (Day 46 ±2 days). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Inje Cocktail Alone and Inje Cocktail Plus Belatacept | — | 0/22 (0%) | 3/22 (13.6%) |
| Event | Inje Cocktail Alone and Inje Cocktail Plus Belatacept |
|---|---|
| HeadacheNervous system disorders | 3/22 |
All participants who received study drug.
| Age, Continuous(years) | Inje Cocktail Alone and Inje Cocktail Plus Belatacept |
|---|---|
| Mean | 31.5 ± 5.96 |
| Sex: Female, Male(Participants) | Inje Cocktail Alone and Inje Cocktail Plus Belatacept |
|---|---|
| Female | 1 |
| Male | 21 |
| Race (NIH/OMB)(Participants) | Inje Cocktail Alone and Inje Cocktail Plus Belatacept |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 7 |
| White | 15 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(participants) | Inje Cocktail Alone and Inje Cocktail Plus Belatacept |
|---|---|
| United States | 22 |
| Body Mass Index (kg/m^2)(kg/m^2) | Inje Cocktail Alone and Inje Cocktail Plus Belatacept |
|---|---|
| Mean | 24.62 ± 2.886 |
The record gives a start of Jan 2013, a primary completion of Apr 2013 and a completion of Apr 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2014, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Caffeine · Losartan · Omeprazole · Dextromethorphan · Midazolam · Abatacept